Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.96) per share and revenue of $16.69 million for the quarter.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The business's quarterly revenue was up 78.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.80) earnings per share. On average, analysts expect Sage Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sage Therapeutics Trading Up 0.5%

NASDAQ SAGE traded up $0.04 during trading hours on Friday, hitting $8.80. 2,933,621 shares of the company's stock traded hands, compared to its average volume of 2,389,153. The business's fifty day moving average price is $8.15 and its two-hundred day moving average price is $7.60. The firm has a market capitalization of $551.06 million, a P/E ratio of -1.52 and a beta of 0.29. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $11.44.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SAGE shares. Wall Street Zen lowered shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th. Scotiabank cut shares of Sage Therapeutics from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $12.00 to $9.20 in a research note on Tuesday, July 8th. Truist Financial set a $9.00 target price on shares of Sage Therapeutics and gave the stock a "hold" rating in a research note on Tuesday, June 17th. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research note on Monday, June 16th. Finally, Robert W. Baird raised their target price on shares of Sage Therapeutics from $7.00 to $9.00 and gave the stock a "neutral" rating in a research note on Friday, June 20th. Two research analysts have rated the stock with a sell rating and fifteen have given a hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $8.23.

Institutional Investors Weigh In On Sage Therapeutics

A hedge fund recently bought a new stake in Sage Therapeutics stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 26,787 shares of the biopharmaceutical company's stock, valued at approximately $213,000. Hedge funds and other institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.